- Home
- INNV vs RGNX Comparison
INNV vs RGNX Comparison
Compare INNV & RGNX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- INNV
- RGNX
- Stock Information
- Founded
- INNV 2007
- RGNX 2008
- Country
- INNV United States
- RGNX United States
- Employees
- INNV N/A
- RGNX N/A
- Industry
- INNV Medical/Nursing Services
- RGNX Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- INNV Health Care
- RGNX Health Care
- Exchange
- INNV Nasdaq
- RGNX Nasdaq
- Market Cap
- INNV 373.3M
- RGNX 387.0M
- IPO Year
- INNV 2021
- RGNX 2015
- Fundamental
- Price
- INNV $3.64
- RGNX $7.52
- Analyst Decision
- INNV Sell
- RGNX Strong Buy
- Analyst Count
- INNV 2
- RGNX 8
- Target Price
- INNV $5.00
- RGNX $31.75
- AVG Volume (30 Days)
- INNV 36.1K
- RGNX 1.1M
- Earning Date
- INNV 05-06-2025
- RGNX 05-12-2025
- Dividend Yield
- INNV N/A
- RGNX N/A
- EPS Growth
- INNV N/A
- RGNX N/A
- EPS
- INNV N/A
- RGNX N/A
- Revenue
- INNV $831,683,000.00
- RGNX $83,328,000.00
- Revenue This Year
- INNV $13.21
- RGNX $285.14
- Revenue Next Year
- INNV $10.29
- RGNX N/A
- P/E Ratio
- INNV N/A
- RGNX N/A
- Revenue Growth
- INNV 12.19
- RGNX N/A
- 52 Week Low
- INNV $2.60
- RGNX $5.04
- 52 Week High
- INNV $6.69
- RGNX $17.52
- Technical
- Relative Strength Index (RSI)
- INNV 66.17
- RGNX 46.69
- Support Level
- INNV $2.84
- RGNX $6.89
- Resistance Level
- INNV $3.18
- RGNX $10.59
- Average True Range (ATR)
- INNV 0.26
- RGNX 0.79
- MACD
- INNV 0.08
- RGNX -0.19
- Stochastic Oscillator
- INNV 98.95
- RGNX 20.67
About INNV InnovAge Holding Corp.
InnovAge Holding Corp is a healthcare delivery platform by several participants focused on providing all-inclusive, capitated care to high-cost, dual-eligible seniors. Its patient-centered care delivery approach improves the quality of care while keeping them in their homes and reducing over-utilization of high-cost care settings such as hospitals and nursing homes. The company's segment includes PACE and others. It generates maximum revenue from the PACE segment.
About RGNX REGENXBIO Inc.
Regenxbio Inc is a biotechnology company. Its main activity is the development and commercialization of recombinant adeno associated virus gene therapy to correct an underlying genetic defect. The diseases that Regenxbio platform targets are metabolic (homozygous familial hypercholesterolemia), neurodegenerative conditions (mucopolysaccharidosis), and retinal diseases (wet age-related macular degeneration, X-linked retinitis pigmentosa). The company derives the majority of its revenue from the United States.